Soffinova Partners

Comet Biorefining, Inc. develops ingredients or syrup blends, plant dietary fibers, dextrose, and animal Nutrition products. The company provides biomass conversion and pretreatment services. The company offers process development, process technology, engineering, business development, project development, and consulting services. Comet Biorefining, Inc. is based in London, Canada.

Catamaran Bio, Inc. develops CAR-NK immune cell therapies for the treatment of tumor. The company develops Tailwind platform to engineer, expand, and process NK cells into allogenic CAR-NK cell therapy shelf products. Catamaran Bio, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.

CrestaTech is developer of cloud-based technologies and services for the smart television sector. CrestaTech’s programmable broadband receivers, all-in-one PCs, notebooks and tablets can support global TV standards with their single reference design. Each device platform is highly programmable with a software-based, multi-standard demodulation capability and flexible front-end interface that allows for the reception and digitization of any global TV signal. CrestatTech’s XC5000 Smart Tuner (TM) ICs are the world’s most highly integrated, high-performance analog and digital silicon TV tuners for flat panel televisions on the market today. With on-board DSP filters, only Xceive ICs provide can service major global analog and digital broadcast television standards. CrestaTech is based in Santa Clara, United States.

Catamaran Bio, Inc. develops CAR-NK immune cell therapies for the treatment of tumor. The company develops Tailwind platform to engineer, expand, and process NK cells into allogenic CAR-NK cell therapy shelf products. Catamaran Bio, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.

Rgenix is a a discovery platform, revolutionizing the treatment of cancer by generating the first-in-class therapeutics that target key nodes in cancer progression. Its proprietary discovery platform is based on innovations in cancer biology that enable the identification and validation of novel post-transcriptionally regulated targets. Rgenix’s productive approach has yielded multiple novel targets to date across several cancer types for which the company is developing drugs, and its scientific approach has led to the discovery of novel therapeutic targets and first-in-class drugs for several cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer, among others. Its aim is to discover and develop safe, effective, and commercially viable therapies that will transform the lives of cancer patients by treating metastatic disease.

Biosyntia ApS operates as a biotechnology company that develops biocatalysts for the fermentation of fine chemicals. The company was incorporated in 2012 and is based in Hørsholm, Denmark.

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines.

MXP4 develops interactive music solutions that create revenue opportunities for the music, media and marketing industries. Creating a video game-like environment where consumers can play with the music, MXP4-powered applications are proven to drive engagement, viral distribution and music purchases. The MXP4 Everywhere roadmap ensures the interactive music technology is readily available in third party services, apps and music formats for implementation by brands, advertisers, media portals, mobile applications, music distribution platforms and third-party music formats. When a fan sees the MXP4 logo on a music app, it means they can play with the music. MXP4 is led by a team of music industry and digital media experts, including former senior executives of Musiwave, Vivendi Mobile Entertainment, EMI Music and DivX. The company is backed by Orkos Capital, Sofinnova Partners and Ventech.

GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.

HighLife SAS, a medtech company, develops novel transcatheter mitral valve replacement system for treating patients suffering from mitral regurgitation. It focuses on providing a minimally invasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. The company was founded in 2010 and is based in Paris, France with an additional office in Irvine, California.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

MXP4 develops interactive music solutions that create revenue opportunities for the music, media and marketing industries. Creating a video game-like environment where consumers can play with the music, MXP4-powered applications are proven to drive engagement, viral distribution and music purchases. The MXP4 Everywhere roadmap ensures the interactive music technology is readily available in third party services, apps and music formats for implementation by brands, advertisers, media portals, mobile applications, music distribution platforms and third-party music formats. When a fan sees the MXP4 logo on a music app, it means they can play with the music. MXP4 is led by a team of music industry and digital media experts, including former senior executives of Musiwave, Vivendi Mobile Entertainment, EMI Music and DivX. The company is backed by Orkos Capital, Sofinnova Partners and Ventech.

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.

EnvoyWorldWide, Inc. provides enterprise notification and message delivery services. Its notification services for business continuity facilitates personalized, interactive voice and text broadcasts, landline phones, faxes, email, pagers, SMS and WAP phones, PDAs, BlackBerrys, and other wireless devices. The company was formerly known as MessageBlaster.com and changed its name to EnvoyWorldWide, Inc. in September, 2000. The company was founded in 1998 and is headquartered in Bedford, Massachusetts.

Oxxius is a laser design and manufacturing house founded in 2002 to bring disruptive innovations to the market of visible lasers. We develop advanced continuous-wave laser modules targeting numerous applications in bio-photonics, metrology, spectroscopy and other analytics and instrumentation applications, for both research and industry customers. Oxxius is headquartered in western France and located among a major optics and photonics cluster. Oxxius’ products leverage an innovative, patented solid-state laser architecture offering major advances in compactness, reliability and cost of ownership. In addition, this technology enables exceptional spectral and spatial beam characteristics, as well as market-leading power levels. We also offer a broad range of diode laser modules to cover all the wavelength range from UV to near-infrared. Together with bringing outstanding products to the market, Oxxius is committed to offering a world-class level of quality, customer care and service.

ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipeline includes QRX-704, QRX-504, QRX-421, QRX-323 etc.

Provide a web application filtering, authentication and intrustion prevention systems.

ReCor Medical has developed a unique therapeutic non-focused ultrasound system for performing renal denervation in patients with resistant hypertension. The PARADISE® technology (Percutaneous Renal Denervation System) includes a 6 French catheter with a cylindrical transducer that emits ultrasound energy circumferentially, allowing for a more efficient renal denervation procedure.

Synthace's goal is to raise universal bioscience productivity, enabling people to better engineer biology for health, food, energy and manufacturing. Central to its technology is Antha, an operating system for biology that enables ease of designing and optimizing biological unit operations that are linked into executable workflows that are reliable, shareable and saleable. Antha spreads biological information in a repeatable way, linking lab equipment, protocols and processes, thereby allowing vast and speedy development, enhancing productivity for any bioscience.

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they are investigating a potential new class of immunotherapy that aims to activate the immune system of patients through the skin.

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they are investigating a potential new class of immunotherapy that aims to activate the immune system of patients through the skin.

Home Biosciences is a European venture builder dedicated to biotech.

iOmx Therapeutics focuses on the development of first-in-class cancer therapeutics addressing novel immune checkpoint modulators on tumor cells. By systematically screening human tumor cells, the Company has already identified a number of novel targets and analyzed their mode of action. The Company was founded on the successful concept of cancer immune-checkpoint therapy, which works by breaking down the inherent resistance mechanisms of tumors against immune attack. Immune resistance of tumors is often mediated by cell surface molecules that stimulate immune-inhibitory receptors on T cells. Reactivating the host immune response by neutralizing these negative interactions is the idea behind cancer immune-checkpoint therapy.

Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Cotherix is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. Ventavis, our lead product candidate, is an inhaled formulation of iloprost.

Polyneuron is a developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patients with immune disorders in a safe and effective manner.

MetGen develops and produces enzymes tailored to industrial customer needs. MetZymes are enzymes belonging to the class of multicopper oxidases. These enzymes are involved in several oxidative functions and particularly in delignification. MetGen have created biological enzymes that can be added into the pulp mix to separate wood fibres more effectively before the thermo-mechanical pulping stage, radically improving the energy efficiency of the whole pulp-making process.

Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.

EryDel S.p.A. engages in the production and commercialization of drug delivery based on the use of autologous erythrocytes. The company provides medical devices which includes red cell loader, and erykit. The company was founded in 2007 and is based in Urbino, Italy.

RefleXion Medical Inc., a medical equipment company, develops a biologically-guided radiotherapy system (BgRT) for cancer treatment. Its technology allows tumors to continuously signal their location during treatment and potentially revolutionize the practice of radiation oncology. The company’s technology also enables simultaneous treatment of tumors throughout the body, as well as real-time dose adaptation to specific biological characteristics of the tumor. RefleXion Medical Inc. has a strategic collaboration agreement with Telix Pharmaceuticals Limited; and a strategic partnership with HealthMyne Inc. The company was incorporated in 2009 and is based in Hayward, California.

Prometheus Materials develops bio-cement with zero carbon emissions to reduce the global CO2 emissions. It aims to push the world towards sustainability. The company was founded in 2021 and is based in Boulder, Colorado.

blueKiwi Software SA provides enterprise social software for financial firms, high-tech, and professional services agencies. It offers blueKiwi 2009, an enterprise social software for people-centric organizations to create social networks and collaborative environments with partners, customers, and colleagues; and blueKiwi Pro, a social software for small and medium businesses. The company also provides strategic consulting and technical services. It has operations in France and the United Kingdom.

Protera is advancing the science of protein engineering to address some of the most critical problems and opportunities in food, agriculture, the environment and human health. We streamline protein design and development with MADI, our proprietary deep learning algorithm, to predict high value protein products and enzymes with unprecedented speed. Our in-house lab generates small quantities of the new predicted structures to validate their desired performance. Upon lab validation, we collaborate with our clients on next steps to move from pilot to industrial scale production.

HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.

NodThera Limited researches and develops novel inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. It develops Inflammasomes, which are multi-protein complexes to treat a range of diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company was incorporated in 2016 and is based in Little Chesterford, United Kingdom with a laboratory in Seattle, Washington; and a corporate office in Lexington, Massachusetts.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Artios Pharma Limited, a biotechnology company, focuses on developing cancer treatments that target DNA damage response (DDR) pathways to selectively kill cancer cells. Its product pipeline includes DNA polymerase theta (Polθ), which is involved in multiple processes associated with DNA repair; an in-licensed program that targets a protein that has been identified as a novel DNA damage response target; and a novel cancer treatment targeting DNA nucleases involved in the DDR. The company was incorporated in 2015 and is headquartered in Cambridge, United Kingdom.

ReVolt Technology is a technology company, which is developing a rechargeable zinc-air battery. ReVolt's batteries may enable more high-power consumer devices, electric vehicles and renewable energy storage. The technology is a result of six years of intense research and development at SINTEF (the largest independent research institute in Scandinavia). Research on material combinations has solved issues historically related to the metal-air technology; power, lifetime and rechargeability.

Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism. Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Mobile security and secure transaction offerings to protect critical assets including connected devices, content, services and transactions.

Microphyt SPAS produces and sells microalgae and other photosynthetic micro-organisms for beauty care and food complement, food, health, and energy markets. The company was incorporated in 2007 and is based in Baillargues, France.

Intransa, Inc. provides products for video security projects. It offers VideoAppliance, which delivers ready out-of-the-box appliances that slash the installation and integration process; EnterpriseServer that delivers installer-ready servers that are tuned and optimized for demands of physical security with Microsoft Server 2008; EnterpriseStorage, which reduces the risk of lost video data; and ViewingStation for remote viewing of multiple high definition streams for video surveillance applications. It serves retail and banking, public safety, manufacturing, transportation, schools and education, gaming and hospitality, government, and health care sectors. The company offers its products through distributors. Intransa, Inc. was founded in 2001 and is headquartered in Menlo Park, California.

DMC Biotechnologies, Inc., a biotechnology company, develops bio-based products using microbial fermentation technology. The company's technology for engineering of microbial hosts enables the production of specialty chemicals, flavors, fragrances, nutraceuticals, natural products, and pharmaceuticals. It develops and deploys Dynamic Metabolic Control technology that reduces the cost and development timeline from discovery to commercial performance. DMC Biotechnologies, Inc. was founded in 2017 and is based in Boulder, Colorado.

Odoo SA develops and installs a suite of open source business application that help the client grow business. The company offers applications to boost sales that include customer relationship management, point of sales, quote builder, mass mailing, survey, events, community builder, lead automation, and live chat; applications to build Websites that include CMS, e-Commerce, blogs, and forum; and application to run operations that include project management, billing, accounting, warehouse management, manufacturing, and procurements. Its software is available online or on-premise. Odoo SA was formerly known as OpenERP SA. The company was founded in 2005 and is based in Ramillies, Belgium.

Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system to treat blindness caused by degeneration of photoreceptor cells in the retina. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC. Pixium Vision SA was founded in 2011 and is based in Paris, France.

Comet Biorefining, Inc. develops ingredients or syrup blends, plant dietary fibers, dextrose, and animal Nutrition products. The company provides biomass conversion and pretreatment services. The company offers process development, process technology, engineering, business development, project development, and consulting services. Comet Biorefining, Inc. is based in London, Canada.

Creabilis is an emerging European specialty pharmaceutical company focused on dermatology. Creabilis discovers, develops and commercialises new medicines for a range of skin disorders, - an area of significant unmet medical need and high commercial potential. Creabilis has an exceptional track record in dermatological research and has used this experience to generate a rich pipeline of clinical and pre-clinical drug candidates that the company will market directly or in partnership. The most advanced product is CT327 for the treatment of psoriasis. CT327 will enter Phase II clinical trials in 2009. Creabilis' pipeline also includes a number of pre-clinical drug candidates arising from its ground breaking drug discovery programmes.

RefleXion Medical Inc., a medical equipment company, develops a biologically-guided radiotherapy system (BgRT) for cancer treatment. Its technology allows tumors to continuously signal their location during treatment and potentially revolutionize the practice of radiation oncology. The company’s technology also enables simultaneous treatment of tumors throughout the body, as well as real-time dose adaptation to specific biological characteristics of the tumor. RefleXion Medical Inc. has a strategic collaboration agreement with Telix Pharmaceuticals Limited; and a strategic partnership with HealthMyne Inc. The company was incorporated in 2009 and is based in Hayward, California.

Pyrowave Inc. develops recycling technology solutions based on the use of microwave to convert plastics into liquid products and brings plastics back to the molecular state identical to virgin materials. The company leases machines for recycling plastics; and sells liquid products and other high-value materials generated during processing. It serves municipal clients, and private recyclers and generators. Pyrowave Inc. was incorporated in 2014 and is headquartered in Oakville, Canada.

MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room.

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.

Corvidia Therapeutics is a clinical stage company focused on the research, development, and commercialization of transformative therapies for cardio-renal diseases. The Company is currently developing potential treatments for chronic kidney disease with atherosclerotic cardiovascular disease and inflammation, and high triglyceride-induced acute pancreatitis.

Twenga provides advanced traffic acquisition solutions for online advertising marketplaces. It helps advertisers to improve performance and the automation of their advertising investments. Twenga employs over 120 people in France, Germany, and England and has over 4000 clients in 15 different countries. Twenga was launched by Bastien Duclaux and Cedric Anes in September 2006 and is based in London, United Kingdom.

CoreValve is a private company founded in 2001 by Jacques Seguin, M.D., Ph.D., a cardiac surgeon. The vision of the Company was to develop a technology that permits the replacement of failing aortic heart valves without surgical access. Developing the concept of a catheter-based aortic valve replacement procedure, the Company has rapidly advanced this technology from vision to reality. Today, more than 200 patients have experienced successful aortic valve replacement with the CoreValve ReValving™ procedure. CoreValve’s objective is to be the technological, clinical, and market leader in percutaneous heart valve replacement therapies. Current efforts are focused on percutaneous aortic valve replacement, but future efforts will relate to other minimally invasive structural heart disease treatments. CoreValve’s headquarters’ are in Irvine, California, an area renowned for the development of innovative heart valve technologies.

Myricx Pharma Ltd provides drug discovery services that develops proprietary inhibitors of human N-myristoyltransferases. It offers myristoylation, a lipid modification that includes cancer, inflammatory conditions, epilepsy, and Alzheimer’s disease solutions. The company was incorporated in 2019 and is based in Stevenage, United Kingdom.

Polyneuron is a developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patients with immune disorders in a safe and effective manner.

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Oxxius is a laser design and manufacturing house founded in 2002 to bring disruptive innovations to the market of visible lasers. We develop advanced continuous-wave laser modules targeting numerous applications in bio-photonics, metrology, spectroscopy and other analytics and instrumentation applications, for both research and industry customers. Oxxius is headquartered in western France and located among a major optics and photonics cluster. Oxxius’ products leverage an innovative, patented solid-state laser architecture offering major advances in compactness, reliability and cost of ownership. In addition, this technology enables exceptional spectral and spatial beam characteristics, as well as market-leading power levels. We also offer a broad range of diode laser modules to cover all the wavelength range from UV to near-infrared. Together with bringing outstanding products to the market, Oxxius is committed to offering a world-class level of quality, customer care and service.

Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.

Sensorion SA, a biopharmaceutical company, develops therapies for the treatment of inner ear disorders. The company develops SENS-111, which is in phase II clinical trials to treat acute unilateral vestibulopathy; and SENS-401 that is in phase I clinical trials to treat sudden sensorineural hearing loss. It also develops SENS-300, which is under the pre-clinical stage for use in inner ear toxicity treatment. The company has a strategic collaboration with Cochlear Limited to study combination therapies for cochlear implant patients. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.

Ingenium Pharmaceuticals AG is discovers and develops molecules for the treatment of neuronal and autoimmune diseases.

Aledia SA develops and manufactures light-emitting diodes (LEDs). The company offers microwire LED chips based on a 3D architecture using gallium-nitride-on-silicon microwires. It provides its products for general lighting, automotive, and display applications. The company was founded in 2011 and is based in Grenoble, France with subsidiaries in Malacca, Malaysia; and Palo Alto, California.

Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.

Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

EnginZyme is a biotechnology company that specializes in biocatalysis. It creates products for easy and cost-efficient implementation of biocatalytic processes and helps the chemical industry transition to a sustainable way of operating. The company is driven by a mission to make biocatalysis the first choice for chemical process designers worldwide.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Synthace's goal is to raise universal bioscience productivity, enabling people to better engineer biology for health, food, energy and manufacturing. Central to its technology is Antha, an operating system for biology that enables ease of designing and optimizing biological unit operations that are linked into executable workflows that are reliable, shareable and saleable. Antha spreads biological information in a repeatable way, linking lab equipment, protocols and processes, thereby allowing vast and speedy development, enhancing productivity for any bioscience.

Curated collection of designer furniture and home accessories from boutiques in Europe

Breath Therapeutics – a Zambon Group Company is pursuing groundbreaking therapies by unleashing the true potential of inhaled drug delivery. Their approach combines novel formulations of existing drugs with cutting-edge inhalation technology for the treatment of rare respiratory diseases with high unmet medical need. They are developing drug-device combinations designed to rapidly deliver high concentrations of drugs to the site of action in the lung. Their approach increases effective dosing in the lung while minimizing systemic exposure which could lead to new treatment solutions with enhanced efficacy and safety.

Meiogenix SAS operates as a biotech company that develops breeding and genomic technologies. It offers SpiX technology, which modulates the process of homologous recombination in the genome by increasing its frequency in cold regions and PhoeniX, which is a non-GM method that induces meiotic recombination in hybrid diploid (or polyploid) yeast cells without the need to go through the entire process of meiosis. The company helps to develop new products to address global food and industrial challenges. The company was incorporated in 2010 and is based in Paris, France.

Intransa, Inc. provides products for video security projects. It offers VideoAppliance, which delivers ready out-of-the-box appliances that slash the installation and integration process; EnterpriseServer that delivers installer-ready servers that are tuned and optimized for demands of physical security with Microsoft Server 2008; EnterpriseStorage, which reduces the risk of lost video data; and ViewingStation for remote viewing of multiple high definition streams for video surveillance applications. It serves retail and banking, public safety, manufacturing, transportation, schools and education, gaming and hospitality, government, and health care sectors. The company offers its products through distributors. Intransa, Inc. was founded in 2001 and is headquartered in Menlo Park, California.

Mobile security and secure transaction offerings to protect critical assets including connected devices, content, services and transactions.

Varioptic SA provides adjustable lens solutions. Its products include variable focus liquid lenses, liquid lens for focus and astigmatism control, auto focus lens modules, microscope auto focus modules, liquid lens driver ICs, and liquid lens development kits. The company’s products are used in industrial, biometrics, medical, and consumer applications. It sells its products through distributors. The company was founded in 2002 and is based in Lyon, France. As of December 29, 2016, Varioptic SA operates as a subsidiary of Invenios France SAS.

HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.

MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room.

Saegis Pharmaceuticals is focused on the development of medicines that address behavioral disorders. The company has a pipeline of treatments for central nervous system diseases involving cognitive dysfunction, including Alzheimer’s disease, mild cognitive impairment, attention deficit hyperactivity disorder, and cognitive impairment associated with schizophrenia. It develops CNS therapeutics for patients facing memory loss and cognition deficits associated with aging, psychiatric disorders, and brain trauma. Saegis Pharmaceuticals was founded in 1999 and is based in Half Moon Bay, California.

Lectus Therapeutics Limited is a UK-based pharmaceutical company. Its mission is to build a development pipeline containing first-in-class ion channel therapeutics identified through the use of its proprietary proteomics technology for pain management and the treatment of urinary bladder disorders.

CorVent Medical is developing smart, versatile, lifesaving ventilators for critical care. The company's first product, the CorVent™ Single-Use Ventilator, was designed in partnership with Design Catapult, an industrial design firm recognized for their rapid ideation of medical and commercial products. The ventilator is currently pending Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA) for ventilators, tubing connectors and accessories, which authorizes its use for the duration of the U.S. Health and Human Services COVID-19 public health emergency declaration.

Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

SafeHeal SAS manufactures an anastomosis protection device, Colovac. The device protects the anastomosis by isolating it from feces and aims to minimize post operative complications, such as staple line leakage. The company was founded in 2015 and is headquartered in Paris, France.

Microphyt SPAS produces and sells microalgae and other photosynthetic micro-organisms for beauty care and food complement, food, health, and energy markets. The company was incorporated in 2007 and is based in Baillargues, France.

NOXXON Pharma AG, a biopharmaceutical company, develops biostable aptamers and substances based on mirror image nucleic acids. Its Spiegelmer is a mirror image oligonucleotide therapeutic for the pharmacologically relevant target. The company has a strategic alliance with Pfizer, Inc. NOXXON Pharma AG was founded in 1997 and is based in Berlin, Germany.

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.

ReVolt Technology is a technology company, which is developing a rechargeable zinc-air battery. ReVolt's batteries may enable more high-power consumer devices, electric vehicles and renewable energy storage. The technology is a result of six years of intense research and development at SINTEF (the largest independent research institute in Scandinavia). Research on material combinations has solved issues historically related to the metal-air technology; power, lifetime and rechargeability.

Protera is advancing the science of protein engineering to address some of the most critical problems and opportunities in food, agriculture, the environment and human health. We streamline protein design and development with MADI, our proprietary deep learning algorithm, to predict high value protein products and enzymes with unprecedented speed. Our in-house lab generates small quantities of the new predicted structures to validate their desired performance. Upon lab validation, we collaborate with our clients on next steps to move from pilot to industrial scale production.

Laszlo Systems provides leading user experience solutions delivering interoperability across applications optimized for mobile and web-enabled devices. Laszlo's web and mobile solutions provide seamless connectivity to multiple backend systems and cloud services while delivering unified user interfaces to dynamically access and share data across applications such as email, contacts, calendar, voice mail. Users can connect to their contacts and social networks, manage a consolidated single list of all their messages (emails, SMS, voice mails, Facebook messages), consume and share media across devices and maintain an aggregated calendar via an intuitive Web interface on their desktops, or straight from their mobile devices and tablets. With Laszlo's solutions, service providers can offer a truly engaging and differentiated experience for integrated communications, messaging and social networking services.

Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact. The company currently works on four development programs: germination, flowering, growth, and weed control.

Varioptic SA provides adjustable lens solutions. Its products include variable focus liquid lenses, liquid lens for focus and astigmatism control, auto focus lens modules, microscope auto focus modules, liquid lens driver ICs, and liquid lens development kits. The company’s products are used in industrial, biometrics, medical, and consumer applications. It sells its products through distributors. The company was founded in 2002 and is based in Lyon, France. As of December 29, 2016, Varioptic SA operates as a subsidiary of Invenios France SAS.

Drug discovery inspired by viruses

AFYREN SAS provides microbiology and bioprocess engineering services to valorize nonfood biomass into bioenergy and green chemistry. It offers services in the areas of methanogen potential measurements; laboratory analysis; tailor-maid research and development for valorization of wastes and organic effluents; and methanation unit feasibility studies in microbiology, chemistry, and bioprocesses sectors. The company serves pharmaceutical, cosmetic, green chemistry, and biopolymer sector. AFYREN SAS was founded in 2012 and is based in Saint-Beauzire, France.

Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.

Pi-Cardia is a medical device start-up company developing a novel low profile catheter for the treatment of aortic stenosis. The company's proprietary technology is based on delivering mechanical impact for creating fractures in valve calcifications, without injuring the surrounding soft tissue. This treatment, which only takes several seconds, is intended to increase the valve effective orifice area without the need to replace the valve.

SafeHeal is the first company created and incubated by MD Start, a medtech accelerator developing innovative medical devices based on inventions from physicians. It is currently funded by MD Start and Sofinnova Partners. SafeHeal is laureate of the Worldwide Innovation Challenge 2015 edition (Concours Mondial de l’Innovation - Phases 1 and 2) and of the iLab grant program, which foster talent and bring out future champions of the French economy. SafeHeal was also elected as the most promising and innovative investor conference MedTech start-up at Biovision 2016, was a finalist for the global Medtech Innovator 2016 competition. Finally, SafeHeal is a 2016 recipient of the Charles Foix grant which rewards innovations aimed at improving the quality of life of elderly people.

ASSIA, Inc provides broadband and Wi-Fi performance monitoring, management and optimization software to internet service providers (ISP), communications regulators, and wholesalers so they can improve customer quality of experience and satisfaction, reduce costs through operational efficiencies and increase revenues with new multi-media services.

ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.